Aardvark Therapeutics, Inc.
AARD
$13.88
$0.322.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 286.55% | 32.24% | 181.64% | 99.43% | 35.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 247.73% | 160.96% | 382.27% | 323.20% | 196.16% |
| Operating Income | -247.73% | -160.96% | -382.27% | -323.20% | -196.16% |
| Income Before Tax | -290.15% | -163.66% | -327.46% | -330.13% | -98.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -290.15% | -163.66% | -327.46% | -330.13% | -98.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.15% | -163.66% | -327.46% | -330.13% | -98.29% |
| EBIT | -247.73% | -160.96% | -382.27% | -323.20% | -196.16% |
| EBITDA | -247.72% | -160.86% | -382.48% | -- | -- |
| EPS Basic | 28.36% | 51.76% | -28.52% | -319.80% | -97.09% |
| Normalized Basic EPS | 26.60% | 52.05% | -35.14% | -302.94% | -156.73% |
| EPS Diluted | 28.36% | 51.76% | -28.52% | -319.80% | -97.09% |
| Normalized Diluted EPS | 26.60% | 52.05% | -35.14% | -302.94% | -156.73% |
| Average Basic Shares Outstanding | 444.62% | 446.63% | 232.59% | 2.46% | 0.61% |
| Average Diluted Shares Outstanding | 444.62% | 446.63% | 232.59% | 2.46% | 0.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |